Skip to main content
OpenTrials
Completed

NCT Number: NCT04640922

Clinical Performance and Safety of the Gedea Pessary in Adult Women With Bacterial Vaginosis

This is a randomised, double-blind placebo-controlled multi-centre study to evaluate clinical performance, safety and local tolerability of initial and preventive treatment with Gedea Pessary in adult women with confirmed BV.

The study population will consist of post-menarchal, pre-menopausal females 18 years or older seeking for BV symptoms (fishy smell, irritation and burning).

Patients will be recruited at study sites' gynaecological and sexual health clinics and a total of 150 patients are planned to be randomised in the study.

On Day 0, patients will have gynaecological examination, vaginal samples taken, and will be randomised in a 4:1 relation to receive treatment with 6 doses of the Gedea Pessary or a vehicle control (placebo) to be self-administered daily (Days 0 to 5). Patients will be re examined at Day 7 (+2 days) for clinical cure rate.

Patients that are clinically cured at Day 7 will continue to the second part of the study and will be randomised in a 1:1 relation to either Gedea Pessary or placebo treatment, to be self administered once a week for a duration of 126 days.

Patients not clinically cured at Day 7 will be offered rescue treatment (metronidazole) for 7 days. They will return at Day 14 for clinical assessment and sampling for microbiome and mycobiome analysis, and if cured they will be assessed for recurrence up to Day 128. Patients that are not cured at Day 14 will be discontinued from the study.

Patients that are clinically cured at Day 7 and continuing in Part 2 will be followed up until confirmed recurrence or Day 128 if no recurrence. Vaginal samples will be taken by self-swab on Days 35, 63 and 91, a visit to the clinic will be performed at Day 63 and telephone follow up will be done at Days 35 and 91. Vaginal samples will also be taken at the visit on the Day of potential recurrence and/or at Day 128 if no recurrence.

Vaginal samples will be used for confirming the diagnosis (Nugent score on Day 0 and Day 7) and sequencing analysis of the vaginal microbiome and mycobiome (Days 0, 7, 35, 63, 91 and Day of confirmed recurrence or Day 128 if no recurrence).

Patient follow-up as regards to patient questionnaire/usability, AEs and BV recurrence notification will be handled with a mobile phone application. In case of a suspected BV recurrence, the patient should return to the clinic for confirmation of BV diagnosis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bacterial Vaginosis Bacterial Infections Bacterial Infections and Mycoses Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Infections Urogenital Diseases Vaginal Diseases Vaginitis Vaginosis, Bacterial

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Hoftekliniken, Helsingborg, Sweden

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult, post-menarchal, pre-menopausal women aged 18 years or older.
  • Diagnosis of BV according to Amsel's criteria, defined as having at least 3 of the 4 criteria.
  • Having decisional capacity and providing written informed consent.
  • Negative urine pregnancy test at screening.
  • Refrain from using any intravaginal products (i.e. contraceptive creams, gels, foams, sponges, lubricants or tampons, etc.) until Day 7 and the following 24 hours after each treatment during weekly treatment.
  • Refrain from sexual intercourse or use a condom until Day 7.
  • Willing to use contraception (if heterosexual) for 128 days.
  • Signed informed consent and willing and able to comply with all study requirements.

Exclusion criteria

  • Patients with known or apparent signs of other infectious causes of vaginitis (e.g.

vulvovaginal candidiasis, Trichomonas vaginalis, Neisseria gonorrhoeae, Chlamydia trachomatis, Herpes simplex, or human papillomavirus) at screening.

  • Anticipated menstruation during the treatment period (Day 0 till Day 5).
  • Patients who are pregnant or breastfeeding.
  • Patients who are planning to conceive within the 128 days study duration.
  • Patients who were treated for BV within the past 14 days.
  • Patients who are currently receiving antibiotic therapy unrelated to BV or have received antibiotic therapy within the past 14 days.
  • Patients who have used pH-modifying vaginal products within the last 14 days.
  • Patients who have received an investigational drug in a clinical investigation within 30 days prior to screening.
  • Known/previous allergy or hypersensitivity to any product constituent.
  • Any medical condition that in the Investigator's judgments would make the patient unsuitable for inclusion.

Treatment and study plan

Gedea Pessary pHyph

Device

Vaginal tablet

PLACEBO

Device

Vaginal tablet

Primary outcomes

  1. Clinical cure rate on Day 7

    Time frame: Day 7

    o Defined as absence of all of the following 3 Amsel criteria:

    • Thin, white, yellow, homogenous discharge;
    • Clue cells on microscopy (more than 20% of epithelial cells);
    • Release of fishy odour "i.e. a positive whiff test" when alkali (10% KOH solution) is added.

Secondary outcomes

  1. Safety and local tolerability of Gedea Pessary - based on reported treatment-emergent AEs up until Day 7.

    Time frame: Day 7

    Part 1

  2. Clinical cure rate on Day 7, defined as clinical cure according to primary endpoint and Nugent score <4, i.e. both criteria have to be fulfilled.

    Time frame: Day 7

    Part 1

  3. Difference between Day 7 and Days 35, 63, 91, 128 and/or Day of possible recurrence confirmation (assessed by Amsel criteria), respectively, in the occurrence of anaerobic vaginal dysbiosis as assessed by analysis of the vaginal microbiome.

    Time frame: Day 35, 63, 91, and 128, respectively

    Part 2

Sponsors and collaborators

Lead sponsor

Gedea Biotech AB

Industry

Registry information

Official study title

A Randomised, Double-blind, Placebo-controlled Study to Evaluate Clinical Performance and Safety of the Gedea Pessary in Adult Women With Bacterial Vaginosis

Acronym: Nefertiti

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Nov 23, 2020
Registry last updated
Aug 18, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.